Literature DB >> 7459888

Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.

C Benz, E Cadman.   

Abstract

The modulation of 5-fluorouracil (FUra) metabolism by methotrexate (MTX) pretreatment in monolayer cultures of human colorectal adenocarcinoma. HCT-8, was examined and correlated to clonal growth of this cell line. There was a gradual and nearly linear total intracellular accumulation and incorporation into RNA of FUra for 30 hr in control cells. A 12-hr 10 microM MTX pretreatment before adding 100 microM FUra resulted in approximately a 3-fold increase in total FUra accumulation, 59% of which was fluorouridine triphosphate. Soluble fluorodeoxyuridine monophosphate was increased 5-fold following MTX pretreatment; however, [3H]deoxyuridine incorporation into the acid-precipitable fraction of cells pretreated with MTX was no more than that observed when FUra was given alone. There was also an increase in 5-phosphoribosyl 1-pyrophosphate pools following MTX which was associated with the enhanced FUra metabolism. The maximum synergistic inhibition of clonal growth occurred when FUra was given during the last 6 hr of a 24-hr MTX exposure period. Other antimetabolites associated with elevations of 5-phosphoribosyl 1-pyrophosphate also resulted in an enhanced total intracellular accumulation of FUra.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7459888

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Phase I trial of the combination of 6-methylmercaptopurine riboside and 5-fluorouracil.

Authors:  M C Wiemann; G W Crabtree; A B Weitberg; E N Spremulli; F J Cummings; C Murray; P Calabresi
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

2.  A phase II study of sequential methotrexate and 5-fluorouracil in colorectal carcinoma.

Authors:  M J Harding; S B Kaye; M Soukop; J C Ferguson
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

3.  Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts.

Authors:  K Wayss; R Herrmann; J Mattern; M Volm
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

4.  Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.

Authors:  J A Ajani; P Goudeau; B Levin; J S Faintuch; J L Abbruzzese; B M Boman; M D Kanojia
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Update in cancer chemotherapy: gastrointestinal cancer--colorectal cancer, Part 2.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-05       Impact factor: 1.798

6.  Lactic dehydrogenase isozymes, 31P magnetic resonance spectroscopy, and in vitro antimitochondrial tumor toxicity with gossypol and rhodamine-123.

Authors:  C Benz; C Hollander; M Keniry; T L James; M Mitchell
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

7.  Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma.

Authors:  C Benz; M Choti; L Newcomer; E Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Lack of enhanced cytotoxicity of cultured L1210 cells using folinic acid in combination with sequential methotrexate and fluorouracil.

Authors:  L L Danhauser; R Heimer; E Cadman
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 9.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

10.  Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.

Authors:  G R Hudes; F LaCreta; R J DeLap; A J Grillo-Lopez; R Catalano; R L Comis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.